Novo Nordisk Sues Eli Lilly Over Alleged Misleading GLP-1 Drug Advertising
Novo Nordisk has filed a lawsuit against Eli Lilly, accusing it of misleading consumers with advertising that claims superior efficacy for its obesity and diabetes drugs. The Danish drugmaker argues that the ads use outdated clinical trials to compare high doses of Lilly's medicines to lower doses of Novo's products.
Topics: advertising regulation obesity drugs pharmaceuticals